An international research team is perfecting a method to predict the potential clinical implications of new drugs before clinical trials even start.
An international research team has developed a new strategy that can predict the potential clinical implications of new therapeutic compounds based on simple cellular responses. This discovery was partly led by scientists affiliated with Université de Montréal (UdeM), and represents a major step forward in developing more effective drugs with fewer side effects, much faster than before. The researchers conducted their work at Centre de Recherche de l’Hôpital Ste-Justine and published their findings in the prestigious journal Nature Communications.
Developing new drugs is a long, complex and costly process. It starts with identifying the molecule or “ligand” (such as a drug, hormone or neurotransmitter) that can activate or block the target or “receptor” involved in a disease. Compound identification and validation is one of the most important steps in ensuring that a new drug provides an effective clinical response with the fewest possible side effects.
“Most new drugs tested on human subjects fail in clinical trials because the therapeutic response is insufficient. Developing a strategy that infers potential clinical responses early in the drug discovery process would significantly improve drug candidate selection,” said Besma Benredjem, the study’s co-lead author and a doctoral student in pharmacology at UdeM.
Finding the needle in a haystack
“Our main goal was finding a way to categorize a large number of drug candidates based on similarities in their effectiveness in triggering a multiplicity of cellular responses that help identify the therapeutic action of new compounds,” said Professor Graciela Piñeyro, co-senior author of the study and a researcher at CHU Sainte-Justine. To accomplish this, she worked with Dr. Olivier Lichtarge of Baylor College of Medicine, who uses advanced bioinformatic analysis to compare and group ligands according to fairly comprehensive signalling profiles.
Drugs produce desired or undesired clinical actions by changing basic signals within cells. By grouping drugs with known clinical actions and new ligands, we can infer the clinical actions of new compounds by comparing the similarities and differences in their signals with known drugs to promote desired clinical responses and avoid side effects.
This method of analysis was developed by using opioid analgesics as prototypes. This made it possible for the team to associate simple cellular signals produced by opioids such as oxycodone, morphine and fentanyl with the frequency with which respiratory depression and other undesirable side effects of these drugs were reported to the Food and Drug Administration’s pharmacovigilance program. At the height of the opioid epidemic, when the risk of death by respiratory depression is at its highest, the team believes this new analytical strategy could lead to the development of safer opioids.
“Thanks to our findings, we can now classify a large number of compounds while taking a multitude of cellular signals into account. The wealth of comparisons this provides increases this classification’s predictive value for clinical responses,” said Professor Michel Bouvier, the study’s co-senior author and a principal investigator of molecular pharmacology and Chief Executive Officer of UdeM’s Institute for Research in Immunology and Cancer. “We think we can help patients by speeding up the drug discovery process so clinical trials can start earlier.”
“Our next goal is to use a similar approach to test cannabis products that may produce harmful neuropsychiatric actions among young people, and identify which cannabis extracts are most effective at treating chronic pain,” added Besma Benredjem.
The Latest on: Drug development
via Google News
The Latest on: Drug development
- House Democrats Push Forward With Drug-Price Negotiation Billon October 17, 2019 at 12:05 pm
Republicans have largely dismissed the measure as damaging to new drug development and the pharmaceutical industry. They’ve pointed to a Congressional Budget Office estimate that as many as 15 new ...
- 101 NC doctors got big money from drug and medical device firms. Here’s what it meanson October 17, 2019 at 10:17 am
OrthoCarolina is proud of the cooperation between drug and device companies and its physicians, spokeswoman Logan Kureczka said in a statement. “Innovation and development of new and improved products ...
- Plexium Debuts With $28M and a New Take on Protein Degradation Drugson October 17, 2019 at 9:44 am
I started getting interested in how I could use my diverse background in computation, physics, and engineering to build tools and techniques for drug development.” Vijayan says the platform, called ...
- Augmented Intelligence Company PercayAI Announces Strategic Partnership with Canopy Biosciences® to Help Researchers Accelerate Drug Discoveryon October 17, 2019 at 8:10 am
"Through our partnership with Canopy Biosciences, scientists will now have access to a powerful and innovative technological service that will help to improve the speed, cost and success rate of ...
- Patient-Derived Tumor Organoid Drug Development Platform Launchedon October 17, 2019 at 5:39 am
SAN DIEGO, Oct. 17, 2019 (GLOBE NEWSWIRE) — Crown Bioscience today announced the launch of a new tumor organoid drug development platform with the potential to significantly improve the predictivity ...
- BioIVT Acquires PPA Research Group, Increasing its Ability to Support Drug Development, Cell and Gene Therapy Researchon October 16, 2019 at 7:41 pm
Acquisition increases BioIVT's access to normal and disease-state leukopaks, plasma and sera, and expands its cell processing capabilities WESTBURY, N.Y., Oct. 16, 2019 /PRNewswire/ -- BioIVT, a ...
- Drug Discovery Informatics Market Size, Share, Opportunities, Development and Global Trend Analysis till 2026on October 16, 2019 at 3:35 am
Launch Of Version 10 Of D360m By Certara® Will Enable Growth Certara®, the global leader in model-informed drug development and regulatory science, announced the launch of version 10 of D360™, a data ...
- Ziopharm Oncology Names Drug Development Leader Dr. Chris Bowden to Board of Directorson October 15, 2019 at 5:01 am
BOSTON, Oct 15, 2019 (GLOBE NEWSWIRE via COMTEX) -- - Industry veteran with 20+ years of global oncology drug development leadership- - Current CMO at Agios Pharmaceuticals; Former VP of Product ...
- Lowman S. Henry: Free market key to new drug developmenton October 14, 2019 at 11:53 am
Second, the inflation penalty would cripple medical research, thereby hindering the development of future treatments. On average, it costs more than $2 billion to bring a new drug to market. And most ...
- Real-World Data Playing a Bigger Role in Drug Developmenton October 11, 2019 at 3:03 pm
"Traditional drug development programs ... don't usually get much insight into who to use a drug in and who not to use a drug in," Woodcock said Thursday at an event on the future of health data ...
via Bing News